Pfizer Expands Recall to All Lots of Chantix Due to Nitrosamine Impurity By Brian Park, PharmD Publish Date September 17, 2021
Bamlanivimab Plus Etesevimab Authorized for Postexposure Prophylaxis for COVID-19 By Brian Park, PharmD Publish Date September 17, 2021
Most With AD, MCI Would Have Been Excluded From Aducanumab Clinical Trials Publish Date September 17, 2021
Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease By Brian Park, PharmD Publish Date September 17, 2021
Presence of ctDNA Predicts Worse Outcomes in Early Breast Cancer By Jen Smith Publish Date September 17, 2021
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer By Jen Smith Publish Date September 17, 2021
Napabucasin Provides No Added Benefit in Metastatic Pancreatic Cancer By Jen Smith Publish Date September 17, 2021
Real-World Data Suggest Vaccination Reduces Risk of COVID-19 in Patients With Cancer By Jen Smith Publish Date September 17, 2021
Long-Term COVID-19 Symptoms Linked to Treatment, Survival of Cancer Patients By Andrea S. Blevins Primeau, PhD, MBA Publish Date September 17, 2021
Cancer Cases in Europe Projected to Increase About 20% by 2040 By Andrea S. Blevins Primeau, PhD, MBA Publish Date September 17, 2021
AbbVie Seeks Approval of Upadacitinib for Ulcerative Colitis By Brian Park, PharmD Publish Date September 16, 2021
Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC By Brian Park, PharmD Publish Date September 16, 2021
Drug Therapy for Borderline Personality Disorder Evaluated By Cassandra Pardini, PharmD Publish Date September 16, 2021
Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma By Brian Park, PharmD Publish Date September 15, 2021
Linzagolix NDA Submitted for Uterine Fibroid Treatment By Brian Park, PharmD Publish Date September 15, 2021
Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint By Brian Park, PharmD Publish Date September 15, 2021
